Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020437 (hypercalcemia)
 10,293 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A newborn infant with subcutaneous fat necrosis and hypercalcemia is presented. Literature on the association between subcutaneous fat necrosis of the newborn and hypercalcemia is reviewed. Affected infants generally experience severe perinatal difficulties. Both vaginal deliveries and cesarean sections can be associated with subcutaneous fat necrosis.
J Am Acad Dermatol 1987 Feb
PMID:Subcutaneous fat necrosis of the newborn with hypercalcemia. 381 90

Squamous cell carcinoma of the skin is a rare complication of hidradenitis suppurativa. We treated a case of hidradenitis-associated squamous cel carcinoma with metastases to the inguinal lymph nodes. Hypercalcemia also occurred, possibly in relation to the secretion of a hormonelike substance by the tumor. Chemotherapy with bleomycin sulfate, methotrexate sodium, and cisplatin led to tumor regression and control of the hypercalcemia.
Arch Dermatol 1985 Feb
PMID:Hypercalcemia in association with cutaneous squamous cell carcinoma. Occurrence as a late complication of hidradenitis suppurativa. 397 41

A rare presentation of hypercalcemia secondary to the probable ectopic production of parathormone by a malignant melanoma associated with a pulmonary carcinoid is discussed. We suggest the association of melanoma with multiple endocrine neoplasia.
J Dermatol Surg Oncol 1983 Jul
PMID:Pulmonary carcinoid associated with a parathormone producing melanoma. 613 87

Sarcoidosis, a multisystem disease of unknown cause characterized by the formation of noncaseating granulomas, may involve any organ of the body, but the commonest sites of predilection are the lungs, lymph nodes, skin, and eyes. Sarcoidosis can be associated with polyclonal hyperglobulinemia, hypercalcemia, hypercalciuria, circulating immune complexes, cutaneous anergy, and in vitro depressed cell-mediated immunity. Recent studies of the cellular composition and cellular interactions of sarcoid-involved tissue have resulted in some insight into the pathophysiology of the disease. In early stages the predominance of activated T-helper cells in affected sites may account for many of the immunologic aberrations. The production of macrophage chemotactic substances by these cells may be the initial stimulus for the formation of the granuloma. The natural history of the disease is highly variable; the acute forms tend to resolve spontaneously, whereas the chronic forms rarely involute. Although multiple therapeutic modalities have been used and some have reportedly been effective, systemic corticosteroids remain the most effective available therapeutic agents.
J Am Acad Dermatol 1984 Jul
PMID:Sarcoidosis. An updated review. 637 53

The growth and differentiation of epidermal cells in vitro show a marked dependence on the calcium concentration of the medium. In this study the effect of experimentally produced hyper- and hypocalcaemia on the rat epidermis in vivo has been investigated. Hypercalcaemia, induced by injections of calcium chloride, produced a decrease in epidermal labelling index and some epidermal thinning. On the other hand hypocalcaemia, induced by calcitonin, failed to lead to changes in these measurements. The diurnal variation in epidermal labelling index and serum calcium levels was also measured. Whilst the labelling index decreased considerably over the period 09.00 hours to 18.00 hours, no significant changes were observed in serum calcium. These results suggest that while, under certain circumstances in vivo, the epidermal cell shows the same sensitivity to calcium as it does in vitro, calcium is not a major regulator of epidermopoiesis.
Br J Dermatol 1984 Aug
PMID:The effect of serum calcium levels on the rate of epidermal renewal in the rat. 654 May 96

A case of calcinosis cutis is presented in a patient with hypercalcemia of unknown etiology. The axillae and inguinal areas were involved and the clinical and histologic picture is compared with pseudoxanthoma elasticum. We propose that the similarities between the two diseases stem from a common origin in damaged elastic fibers.
J Am Acad Dermatol 1983 Jan
PMID:An unusual case of calcinosis cutis. 682 92

The clinical course of three patients with cutaneous T-cell lymphoma (CTCL) in whom skeletal disease developed is presented and the literature on skeletal involvement in these disorders is reviewed. Three separate types of skeletal manifestations occurred: (1) osteolytic lesions, (2) osteoblastic lesions, and (3) diffuse osteoporosis. Hypercalcemia was present in two cases. Tumor cells from two patients in short-term culture secreted osteoclast-activating factor(s). Both of these patients had pathologic evidence of osteoclast activation in bone sections. Thus, the tumor cells in certain patients with CTCL may derive from a monoclonal proliferation of a T-cell subset capable of producing humoral bone-resorbing factor(s) similar to those demonstrated in cultures of mitogen- and antigen-activated normal lymphocytes. Since skeletal lesions are unusual, it would follow that other T-cell subsets account for pathologic cell proliferation in most patients with CTCL.
Arch Dermatol 1982 Jul
PMID:Skeletal manifestations in cutaneous T-cell lymphomas. 697 76

A female infant who was anoxic at birth had lesions of subcutaneous fat necrosis at the age of 16 days. She also had problems with poor feeding, frequent vomiting, and failure to thrive. Hypercalcemia was discovered at the age of 28 days and she died at 11 1/2 weeks despite return of the serum calcium level to normal with oral prednisone therapy and a diet low in calcium and devoid of vitamin D. Fourteen other cases of idiopathic hypercalcemia in patients with subcutaneous fat necrosis of the newborn have been reported. Most of these infants were full-term with prenatal complications. The hypercalcemia was usually diagnosed much later than the subcutaneous fat necrosis. Both conditions generally resolved without sequelae, but two of the 14 infants died. The causal relation between these two entities, if one exists, remains unknown. Infants with subcutaneous fat necrosis should have serial serum calcium determinations and should be observed closely for signs and symptoms of hypercalcemia, which include irritability, anorexia, constipation, and failure to thrive.
Arch Dermatol 1980 Oct
PMID:Subcutaneous fat necrosis of the newborn and idiopathic hypercalcemia. Report of a case. 742 62

We present two patients with subcutaneous fat necroses (SCFN) in whom endocrinologic studies revealed an association with elevated prostaglandin E (PGE) levels. A boy born after prolonged labor complicated by meconium aspiration developed erythematous, indurated plaques over the back, arms, buttocks, and cheeks at 4 days of age. A biopsy specimen of involved skin showed panniculitis with foci of necrotic adipocytes containing radially arranged, needle-shaped clefts and a granulomatous infiltrate in the septae. Laboratory studies revealed hypercalcemia of 13.6 mg/dl (normal 8.8-10.1 mg/dl), elevated 1.25-1.25(OH)2D3, and increased urinary excretion of PGE2. The child was hospitalized and treated with systemic steroids and diuretics, with resolution of SCFN and hypercalcemia. The second patient was a girl born with cyanotic heart disease. A diagnosis of Ebstein anomaly was made, and intravenous PGE1 was started to keep patent the ductus arteriosus. Four days later erythematous, indurated plaques were noted on the knee, back, and anterior chest. A skin biopsy specimen revealed SCFN. There was no associated laboratory abnormality. On discontinuing PGE1, no new lesions formed and the existing panniculitis resolved. These two cases demonstrate the association between SCFN and elevated PGE levels (endogenous in patient 1, exogenous in patient 2). No previous reports of SCFN after the administration of PGE1 have appeared in the literature.
Pediatr Dermatol 1995 Mar
PMID:Subcutaneous fat necrosis, hypercalcemia, and prostaglandin E. 779 19

Vitamin D topical analogues are now considered an excellent adjunct to the therapy of psoriasis. Systemic vitamin D3 treatment has been used occasionally, especially in case of associated hypocalcemia. We report five patients (aged 6, 16, 36, 58 and 79 years) successfully treated with vitamin D3 per os. Four had erythrodermic and/or pustulous psoriasis, and two of these had concomitant hypocalcemia. The fifth patient was a girl with pseudohypoparathyroidism and psoriasis vulgaris. The association of hypocalcemia and severe psoriasis is classical and was an incentive to try vitamin D treatment. A review of the literature showed that vitamin D can also be reported as a treatment of psoriasis vulgaris. Hypercalciuria and hypercalcemia are limiting risks. However calcium toxicity seems to be minor when vitamin D is given once a day at bedtime in doses lower than 2 micrograms/24 h. Double blind studies should be performed to determine the real efficacy of this treatment.
Ann Dermatol Venereol 1993
PMID:[Treatment of psoriasis by oral calcitriol. A study of 5 cases and review of the literature]. 783 59


<< Previous 1 2 3 4 5 6 7 8 Next >>